Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rideau CBD
- Development stage
- Preclinical
- Lead developer
- Tilray
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Rideau CBD** is a high-CBD, low-THC cannabis oil product developed by Aphria, featuring approximately 23-27 mg/ml CBD and less than 0.7-1 mg/ml THC, classified as sativa-dominant. It is formulated for oral administration and has been utilized in clinical research, including a pharmacokinetics study in Argentina for treating refractory epilepsy in children involving 100 patients over 2.5 years. Cannabidiol (CBD), its primary active ingredient, interacts with the endocannabinoid system to exert anti-inflammatory, analgesic, anxiolytic, and anticonvulsant effects without psychoactive activity, though it carries risks of liver injury and drug interactions. Unlike FDA-approved Epidiolex (pure CBD), Rideau CBD is a whole-plant extract not evaluated for specific therapeutic claims.
- Brand names
- Rideau CBDRideau Oil
- Other names
- Aphria Rideau CBD Sativa OilRideau Platinum CBD Oil
02
Targets
CNR1 (Cannabinoid receptor 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on Rideau CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rideau CBD.